| The development of robust, optimized manufacturing processes early in process development is essential to enable future scale-up of therapeutic MSCs to clinically-relevant volumes. This application note describes using an efficient DOE approach to process optimization in a scale-down model.
Read to learn about: Screening several process parameters simultaneously in multi-parallel bioreactors with real-time monitoring of CPPs
Generating process insight through MVDA correlation of CPPs and CQAs Setting design space for successful future scale-up | 